Coherus Oncology (CHRS) Gains from Investment Securities (2013 - 2019)
Coherus Oncology (CHRS) reported Gains from Investment Securities of $43000.0 for Q4 2019, up 530.0% on a YoY basis from $6825.4 in Q4 2018, and up 760.0% sequentially from $5000.0 in Q3 2019.
Coherus Oncology (CHRS) Gains from Investment Securities (2013 - 2019) Analysis & Trends
Coherus Oncology (CHRS) has 7 years of Gains from Investment Securities data on file, last reported at $43000.0 in Q4 2019.
- For the quarter ending Q4 2019, Gains from Investment Securities rose 530.0% year-over-year to $43000.0; the trailing twelve-month figure through Dec 2019 stood at $52000.0 (down 98.56% YoY), and the FY2019 full-year result was $42000.0, up 101.3% from the prior year.
- Gains from Investment Securities climbed to $43000.0 in Q4 2019, from $5000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $5.1 million in Q2 2016 to a low of -$1.6 million in Q3 2016.
- A 5-year average of $861789.5 and a median of $185000.0 in 2015 frame the typical range for Gains from Investment Securities.
- Peak annual rise in Gains from Investment Securities reached 7746.15% in 2016, while the deepest fall reached 1085.19% in 2016.
- Tracing CHRS's Gains from Investment Securities over 5 years: stood at $185000.0 in 2015, then soared by 202.7% to $560000.0 in 2016, then decreased by 5.36% to $530000.0 in 2017, then tumbled by 101.89% to -$10000.0 in 2018, then jumped by 530.0% to $43000.0 in 2019.
- Business Quant data shows CHRS's Gains from Investment Securities at $43000.0 in Q4 2019, $5000.0 in Q3 2019, and $4000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Coherus Oncology | 200.42 Mn | 33.38 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 43,000.00 |
| Dec 31, 2019 | 43,000.00 |
| Sep 30, 2019 | 5,000.00 |
| Sep 30, 2019 | 5,000.00 |
| Mar 31, 2019 | 4,000.00 |
| Mar 31, 2019 | 4,000.00 |
| Dec 31, 2018 | -10,000.00 |
| Dec 31, 2018 | -10,000.00 |
| Sep 30, 2018 | 25,000.00 |
| Sep 30, 2018 | 25,000.00 |
| Jun 30, 2018 | 3.40 Mn |
| Jun 30, 2018 | 3.40 Mn |
| Mar 31, 2018 | 208,000.00 |
| Mar 31, 2018 | 208,000.00 |
| Dec 31, 2017 | 530,000.00 |
| Dec 31, 2017 | 530,000.00 |
| Sep 30, 2017 | -300,000.00 |
| Sep 30, 2017 | -300,000.00 |
| Jun 30, 2017 | 3.50 Mn |
| Jun 30, 2017 | 3.50 Mn |